Home Newsfeeds Netcapital Q3 EPS $0.33, Sales $2.26M

Netcapital Q3 EPS $0.33, Sales $2.26M

Netcapital (NASDAQ:NCPL) reported quarterly earnings of $0.33 per share. The company reported $2.26 million in sales this quarter.

byMichael Horton

March 16, 2023

1 minute read

Netcapital (NASDAQ:NCPL) reported quarterly earnings of $0.33 per share. The company reported $2.26 million in sales this quarter.

Deutsche Bank Initiates Coverage On Owens-Corning with Hold Rating, Announces Price Target of $103

By Benzinga Newsdesk

August 18, 5:03 AM

Deutsche Bank analyst Joe Ahlersmeyer initiates coverage on Owens-Corning (NYSE:OC) with a Hold rating and announces Price Target of $103.

Private Division Faces Closure: Take-Two To Sell Or Shutter Studios: Report

By Franca Quarneti

June 3, 3:54 PM

Discover the inside scoop on Take-Two's covert dismantling of indie label Private Division, as studios like Intercept Games and Roll7 face closure.

TTWO

Bitcoin Falls Sharply, Terra Classic, ApeCoin Among Top Losers

By Lisa Levin

August 16, 10:35 AM

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices trading below the $29,100 level on Wednesday. Ethereum (CRYPTO: ETH) also recorded losses, but remained above the $1,800 mark this morning.

$APE

News

Immutep Announced Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

By Charles Gross

September 14, 5:05 AM

Immutep Limited (ASX: IMM; NASDAQ: IMMP) provides a clinical development update for its first-in-class LAG-3 antigenpresenting cell (APC) activator product candidate, eftilagimod alpha ("efti").

IMMP

Netcapital Q3 EPS $0.33, Sales $2.26M

Related Posts

Deutsche Bank Initiates Coverage On Owens-Corning with Hold Rating, Announces Price Target of $103

Private Division Faces Closure: Take-Two To Sell Or Shutter Studios: Report

Bitcoin Falls Sharply, Terra Classic, ApeCoin Among Top Losers

Immutep Announced Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha